{"cursor":"5569","size":15,"audio":[],"currentlang":"en","article":"{{Drugbox\n| Verifiedfields = changed verifiedrevid = 477373749 IUPAC_name = 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-\n| yl)propoxy]quinoline-3-carbonitrile image = Bosutinib.png image2 = Bosutinib\n| ball-and-stick from 3UE4.png\n\n\n| tradename = Bosulif licence_US = Bosutinib pregnancy_AU =  pregnancy_US = D pregnancy_category = legal_AU =  legal_CA =  legal_UK =  legal_US = Rx-only legal_status = routes_of_administration = Oral\n\n\n| bioavailability = protein_bound = 94â96% metabolism = By CYP3A4, to inactive\n| metabolites elimination_half-life = 22.5Â±1.7 hours excretion = Fecal (91.3%)\n| and renal (3%)\n\n\n| CAS_number_Ref = CAS_number = 380843-75-4 ATC_prefix = L01 ATC_suffix = XE14\n| ATC_supplemental = ChEBI_Ref = ChEBI = 39112 PubChem = 5328940 DrugBank_Ref =\n| DrugBank = UNII_Ref = UNII = 5018V4AEZ0 ChEMBL_Ref = ChEMBL = 288441\n| ChemSpiderID_Ref = ChemSpiderID = 4486102 SMILES =\n| Clc1c(OC)cc(c(Cl)c1)Nc4c(C#N)cnc3cc(OCCCN2CCN(CC2)C)c(OC)cc34 InChI = 1/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-\n| 3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-\n| 3H3,(H,30,31) InChIKey = UBPYILGKFZZVDX-UHFFFAOYAE StdInChI_Ref = StdInChI =\n| 1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-\n| 3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-\n| 3H3,(H,30,31) StdInChIKey_Ref = StdInChIKey = UBPYILGKFZZVDX-UHFFFAOYSA-N\n\n\n| chemical_formula = C=26 | H=29 | Cl=2 | N=5 | O=3 molecular_weight =\n| 530.446 g/mol\n}}\n\n'Bosutinib' (rINN/USAN; codenamed SKI-606, marketed under the trade name\n'Bosulif') is a tyrosine kinase inhibitor undergoing research for use in the\ntreatment of cancer.  Puttini M, Coluccia AM, Boschelli F, Cleris L,\nMarchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V,\nAndreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C. In vitro and in vivo\nactivity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-\nAbl+ neoplastic cells. Cancer Res. 2006 Dec 1;66(23):11314-22. Epub 2006 Nov 17.\n  Originally synthesized by Wyeth, it is\nbeing developed by Pfizer.\n\nSome commercial stocks of bosutinib (from sources other than the Pfizer material\nused for clinical trials) have recently been found to have the incorrect\nchemical structure, calling the biological results obtained with them into doub-\nt. [http://pipeline.corante.com/archives/2012/05/14/bosutinib_dont_believe_-\nthe_label.php Derek Lowe, In The Pipeline (blog), \"Bosutinib: Don't Believe the\nLabel!\"]\n\nBosutinib received US FDA approval on September 4, 2012 for the treatment of\nadult patients with chronic, accelerated, or blast phase Philadelphia chromosome-\npositive (Ph+) chronic myelogenous leukemia (CML) with resistance, or\nintolerance to prior therapy. Cortes JE, Kantarjian HM, BrÃ¼mmendorf TH, Kim\nDW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N,\nAbbas R, Wang J, Leip E, Gambacorti-Passerini C. Safety and efficacy of\nbosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic\nmyeloid leukemia patients with resistance or intolerance to imatinib. Blood.\n2011 Oct 27;118(17):4567-76. Epub 2011 Aug 24. Cortes JE, Kim DW,\nKantarjian HM, BrÃ¼mmendorf TH, Dyagil I, Griskevicus L, Malhotra H, Powell C,\nGogat K, Countouriotis AM, Gambacorti-Passerini C. Bosutinib Versus Imatinib in\nNewly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA\nTrial. J Clin Oncol. 2012 Sep 4. [Epub ahead of print] \n","linknr":-1,"url":"bosutinib","recorded":1376428370,"links":[],"instances":[],"pdf":[],"categories":["Non-receptor tyrosine kinase inhibitors","Piperazines","Phenol ethers","Quinolines","Nitriles","Anilines","Organochlorides"],"headings":["See also","References","External links"],"image":[],"tags":[],"members":[],"related":["CYP3A4","International_Nonproprietary_Name","United_States_Adopted_Name","Tyrosine_kinase_inhibitor","Wyeth","Pfizer","Food_and_Drug_Administration","Chronic_myelogenous_leukemia","Imatinib","Discovery_and_development_of_Bcr-Abl_tyrosine_kinase_inhibitors"]}